Announcements Trials

Browse Landscape

Phase

Phase 3 14 Phase 2 11 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Dermatologic 1

Conditions

Rhabdomyosarcoma 1

Interventions

Temozolomide 33 Radiotherapy 32 pembrolizumab 18 Cyclophosphamide 18 Irinotecan 16 Gemcitabine 16 Doxorubicin 16 Nivolumab 11 Docetaxel 11 Sirolimus 10 Imatinib Mesylate 10 Ifosfamide 10 Filgrastim 10 Radiation 9 Bevacizumab 9 Vincristine 8 Carboplatin 8 pazopanib 7 Everolimus 7 temsirolimus 6 atezolizumab 6 Peripheral Blood Stem Cell Transplantation 6 Etoposide 6 fludarabine phosphate 5 Vorinostat 5 Specimen Handling 5 Radiotherapy, Conformal 5 PM 01183 5 Ipilimumab 5 Erlotinib Hydrochloride 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Dactinomycin × Sarcoma × Clear all

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡